Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29886
Title: Vascular function in the diagnostic categories of polycystic ovary syndrome.
Authors: Moran L.J.;Teede H.J. ;Cameron J.D.;Strauss B.J.
Institution: (Moran, Teede) Jean Hailes Clinical Research Unit, School of Public Health and Preventive Medicine, Monash University, Clayton 3168, Australia (Cameron) Monash Cardiovascular Research Centre, Monash University, Clayton 3168, Australia (Cameron) La Trobe University, Melbourne 3086, Australia (Strauss) Departments of Medicine, Nutrition and Dietetics, Monash University, Clayton 3168, Australia (Teede) Diabetes Unit, Southern Health, Clayton, 3168, Australia
Issue Date: 26-Jul-2011
Copyright year: 2011
Publisher: Oxford University Press
Place of publication: United Kingdom
Publication information: Human Reproduction. 26 (8) (pp 2192-2199), 2011. Date of Publication: August 2011.
Journal: Human Reproduction
Abstract: Background: Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular disease (CVD). However, it is unknown whether CVD risk is equivalent across the different diagnostic categories or phenotypes of PCOS, particularly in the new phenotypes that affect up to 50 of women with PCOS. Surrogate markers of CVD include endothelial function and arterial stiffness that are independent risk factors for CVD. The primary aim of this study was to assess whether milder phenotypes of PCOS have elevated CVD risk compared with controls. Method(s): This was a cross-sectional study, conducted in an academic medical centre, of overweight premenopausal women with either National Institute of Health (NIH) PCOS (n=29) or milder non-NIH PCOS (n=25) and controls without PCOS (n=27). Primary outcomes were markers of vascular health, including endothelial function [peripheral arterial tonometry (PAT), asymmetric dimethylarginine (ADMA) and plasminogen activator inhibitor-1 (PAI-1)] and arterial stiffness [central pulse wave velocity (PWVc)]. Secondary outcomes were insulin resistance, glucose tolerance and inflammation (C-reactive protein). Result(s): ADMA was significantly different across the three groups (P=0.003). ADMA was similar for NIH and non-NIH PCOS (0.56 +/- 0.01 versus 0.53 +/- 0.02 mol/l, P=1.0) and higher for both NIH PCOS compared with controls (0.56 +/- 0.01 versus 0.46 +/- 0.02 mol/l, P 0.003) and non-NIH PCOS compared with controls (0.53 +/- 0.02 versus 0.46 +/- 0.02 mol/l, P=0.046). PAI-1 (P=0.20), PAT (P= 0.95) and PWVc (P=0.67) were similar for the three groups. All Results were maintained after adjustment for age and body mass index where significant differences in these potentially confounding factors occurred between groups. Conclusion(s): Women with NIH and non-NIH PCOS have elevated ADMA compared with controls independent of age and adiposity. This suggests that CVD risk, reflected by endothelial dysfunction, is increased in both traditional NIH and new milder non-NIH PCOS phenotypes. However, no differences in other markers of endothelial function or arterial stiffness were apparent between phenotypes in this PCOS cohort. © 2011 The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/humrep/der159
PubMed URL: 21616917 [http://www.ncbi.nlm.nih.gov/pubmed/?term=21616917]
ISSN: 0268-1161
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/29886
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

22
checked on Feb 7, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.